Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range

Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range


Waystar CEO: We're building a visible, recurring revenue business driving profitable growth

Waystar shares slid about 3% in their Nasdaq debut on Friday, after the health-care payment software vendor priced its IPO in the middle of the expected range.

The stock opened at $21 per share, below the IPO price of $21.50 late Thursday. Waystar said its expected price would be between $20 and $23 per share in May. Shares closed down more than 3% to $20.70 on Friday.

The IPO market has been largely dormant since late 2021 when the extended bull market turned and investors began to worry about a weakening economy. Few technology companies have been willing to try and go public since then, and no digital health companies had a public exit in 2023, according to a report from Rock Health.

But the broader venture-backed tech market may be beginning to thaw. Social media platform Reddit, data center connectivity chip vendor Astera Labs and data software management maker Rubrik have all gone public this year. Health tech company Tempus AI has also issued a preliminary prospectus this year.

Based on Waystar’s initial share price, the company’s market cap is about $3.5 billion. The stock is trading under the ticker symbol “WAY.”

Waystar offers health-care payment and revenue cycle management tools and facilitates more than 5 billion payment transactions annually, according to its prospectus. The company was formed in 2017 after the health-care payment companies Navicure and ZirMed merged.

“We’re excited about the opportunity to be a public company because we think it helps us with awareness, helps us with credibility, helps us improve our capital structure and allows for further investments in areas such as generative AI,” Waystar CEO Matt Hawkins told CNBC’s “The Exchange” Friday.

For the quarter ending March 31, Waystar generated revenue of $224.8 million, up 18% from $191.1 million in the same period last year. Waystar reported a net loss of $15.9 million for the quarter compared with $10.6 million a year ago.

The company said it plans to use the money from the offering to pay off existing debt. JPMorgan Chase, Goldman Sachs and Barclays are leading the offering.

WATCH: Tech IPOs face hurdle

Startup valuations' impact on IPOs



Source

Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula
Health

Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula

Laura Modi, co-founder and CEO of infant formula startup Bobbie, is on a mission to transform an industry that she says has been stagnant for decades, and shift the culture around how parents feed their babies. Modi, a former Airbnb executive, came up with the idea for Bobbie after the birth of her first child. […]

Read More
Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Health

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]

Read More
Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug
Health

Healthy Returns: Pfizer’s new obesity bet, Metsera, releases encouraging data on lead drug

Thomas Fuller | SOPA Images | Lightrocket | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer‘s newest bet on obesity is already showing promise.  The company last week said it would buy […]

Read More